In addition, NRAS mutations are prevalent in approximately 25% of melanoma and display an even more aggressive tumour progression than their BRAF-mutated counterparts, although the role of NRAS mutations only serve as a prognostic factor [2]. The gene discussed is BRAF; the disease is neoplasm.